0

Randomized Comparison of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome and Planned Invasive Strategy--Design and Rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial

Stefanie Schulz, Dominick J Angiolillo, David Antoniucci, Isabell Bernlochner, Christian Hamm, Juliane Jaitner, Karl-Ludwig Laugwitz, Katharina Mayer, Barbara von Merzljak, Tanja Morath, Franz-Josef Neumann, etc.

J Cardiovasc Transl Res. 2014 Feb;7(1):91-100.

PMID: 24371012

Abstract:

In acute coronary syndromes (ACS), a dual antiplatelet regimen with an adenosine diphosphate (ADP) receptor antagonist plus aspirin has become the cornerstone of treatment. The third-generation thienopyridine prasugrel and the cyclopentyl-triazolo-pyrimidine ticagrelor provide a greater, more rapid and consistent platelet inhibition compared to their predecessor clopidogrel. Based on their advantages over clopidogrel in two landmark studies, both drugs received a class I recommendation for their use in ACS patients with and without ST segment elevation. Due to differences in ACS populations and conditions investigated, the relative merits of ticagrelor versus prasugrel in the treatment of ACS patients with planned invasive strategy cannot be reliably estimated from independent trials. To date, no direct head-to-head comparison of ticagrelor and prasugrel in terms of clinical outcome exists. The aim of this multicenter, randomized, open-label trial is to assess whether ticagrelor is superior to prasugrel in ACS patients with planned invasive strategy.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP150322433 Prasugrel Prasugrel 150322-43-3 Price
qrcode